Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
CNS Neurosci Ther. 2024 Jun;30(6):e14822. doi: 10.1111/cns.14822.
Despite the extensive neurological symptoms induced by COVID-19 and the identification of SARS-CoV-2 in post-mortem brain samples from COVID-19 patients months after death, the precise mechanisms of SARS-CoV-2 invasion into the central nervous system remain unclear due to the lack of research models.
We collected glioma tissue samples from glioma patients who had a recent history of COVID-19 and examined the presence of the SARS-CoV-2 spike protein. Subsequently, spatial transcriptomic analyses were conducted on normal brain tissues, glioma tissues, and glioma tissues from glioma patients with recent COVID-19 history. Additionally, single-cell sequencing data from both glioma tissues and glioma organoids were collected and analyzed. Glioma organoids were utilized to evaluate the efficacy of potential COVID-19 blocking agents.
Glioma tissues from glioma patients with recent COVID-19 history exhibited the presence of the SARS-CoV-2 spike protein. Differences between glioma tissues from glioma patients who had a recent history of COVID-19 and healthy brain tissues primarily manifested in neuronal cells. Notably, neuronal cells within glioma tissues of COVID-19 history demonstrated heightened susceptibility to Alzheimer's disease, depression, and synaptic dysfunction, indicative of neuronal aberrations. Expressions of SARS-CoV-2 entry factors were confirmed in both glioma tissues and glioma organoids. Moreover, glioma organoids were susceptible to pseudo-SARS-CoV-2 infection and the infections could be partly blocked by the potential COVID-19 drugs.
Gliomas had inherent traits that render them susceptible to SARS-CoV-2 infection, leading to their representability of COVID-19 neurological symptoms. This established a biological foundation for the rationality and feasibility of utilization of glioma organoids as research and blocking drug testing model in SARS-CoV-2 infection within the central nervous system.
尽管 COVID-19 会引发广泛的神经系统症状,并且在 COVID-19 患者死亡数月后的尸检脑组织样本中也发现了 SARS-CoV-2,但由于缺乏研究模型,SARS-CoV-2 入侵中枢神经系统的确切机制仍不清楚。
我们收集了最近有 COVID-19 病史的胶质瘤患者的胶质瘤组织样本,并检测了 SARS-CoV-2 刺突蛋白的存在。随后,对正常脑组织、胶质瘤组织和最近有 COVID-19 病史的胶质瘤患者的胶质瘤组织进行了空间转录组分析。此外,还收集和分析了胶质瘤组织和胶质瘤类器官的单细胞测序数据。利用胶质瘤类器官评估了潜在 COVID-19 阻断剂的疗效。
最近有 COVID-19 病史的胶质瘤患者的胶质瘤组织中存在 SARS-CoV-2 刺突蛋白。最近有 COVID-19 病史的胶质瘤患者的胶质瘤组织与正常脑组织之间的差异主要表现在神经元细胞中。值得注意的是,有 COVID-19 病史的胶质瘤组织中的神经元细胞对阿尔茨海默病、抑郁症和突触功能障碍表现出更高的易感性,表明存在神经元异常。在胶质瘤组织和胶质瘤类器官中均证实了 SARS-CoV-2 进入因子的表达。此外,胶质瘤类器官易受伪 SARS-CoV-2 感染,潜在的 COVID-19 药物可部分阻断感染。
胶质瘤具有固有特性,使其易受 SARS-CoV-2 感染,从而代表 COVID-19 的神经系统症状。这为利用胶质瘤类器官作为 SARS-CoV-2 感染中枢神经系统的研究和阻断药物测试模型的合理性和可行性提供了生物学基础。